The financials
Nuvation Bio Inc. by the numbers
Nuvation Bio Inc. (NUVB) reported revenue of $83M in Q1 2026 (quarter ended Mar 31, 2026), up 2599% from the same quarter a year earlier. That came with net income of $5.4M (6.5% of revenue). For the full year FY2025, revenue was $63M (+699% year on year) and net income −$205M. Its largest product in Jun 2026 was Product at $23M, 66% of the disclosed total, well ahead of License at 24%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $83M | $3.1M | +2599% |
| Gross profit | n/a | $990K | n/a |
| Operating income | $3.9M | −$59M | to a profit |
| Net income | $5.4M | −$53M | to a profit |
| Diluted EPS | $0.01 | −$0.16 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Product | $23M | 66% |
| License | $8.5M | 24% |
| Research And Development Service | $2.0M | 5.7% |
| Royalty | $1.6M | 4.5% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $35.3M (-59%)
Product grew +2800% year on yearResearch And Development Service -9.1% year on year
Segment Latestquarter on quarteryear on year
- Product$23.2M$23.2MQoQ +25%year on year +2800%+25%+2800%
- License$8.5M$8.5MQoQ -87%year on year +136%-87%+136%
- Research And Development Service$2.0M$2.0MQoQ +186%year on year -9.1%+186%-9.1%
- Royalty$1.6M$1.6MQoQ +14%year on year +700%+14%+700%